Oncology
Personalised Cancer Vaccines Show Longer-Term Staying Power
Five-year data for intismeran autogene plus pembrolizumab strengthen the case for individualized neoantigen therapy in high-risk resected melanoma.
AI Pathology Starts Moving Toward Treatment Selection
AI Multiomics Moves Into the Trial Stratification Layer
A New CELMoD Raises the Bar in Relapsed Myeloma
IPM Alliance launches at the World Health Assembly in Geneva
IAPM Launches Oncology Pillar at ASCO: Closing the Gap Between Cancer Breakthroughs and Patient Access
WHA 2026: WHO resolution moves precision medicine onto the global health policy agenda
ASCO 2026: Pancreatic cancer gets its precision medicine moment
ASCO 2026: GI cancers are finally moving out of oncology’s blind spot
ASCO 2026: AI is entering cancer care before the rules are ready
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.